State NH
Clinical Trials in New Hampshire
New Hampshire is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in New Hampshire and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.
Right now ClinicalMetric tracks 48 actively recruiting studies with New Hampshire sites out of 48 registered in total. The busiest research areas in New Hampshire are Growth Hormone Deficiency, Stroke, Anatomic Stage II Breast Cancer AJCC v8. Leading sponsors running trials in the state include Dartmouth-Hitchcock Medical Center, National Cancer Institute (NCI), Children's Oncology Group. By stage, New Hampshire trials break down as Phase 1 (1), Phase 2 (14), Phase 3 (16).
All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.
Top Conditions in New Hampshire
Frequently Asked Questions — Clinical Trials in New Hampshire
How many clinical trials are currently recruiting in New Hampshire?
ClinicalMetric currently tracks 48 actively recruiting clinical trials with at least one location in New Hampshire. The total number of registered studies—including active but not currently enrolling trials—is 48. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in New Hampshire?
New Hampshire hosts clinical trials across a broad range of medical conditions, including Growth Hormone Deficiency, Stroke, Anatomic Stage II Breast Cancer AJCC v8, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout New Hampshire serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in New Hampshire?
To join a clinical trial in New Hampshire, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in New Hampshire maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in New Hampshire
NCT07244263 Phase 2
Recruiting
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Condition
Hidradenitis Suppurativa
Enrollment
90 pts
Location
United States, Australia, Canada
Sponsor
Takeda
NCT05955339 N/A
Recruiting
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness C...
Condition
Diabetes Mellitus
Enrollment
1,022 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT07428629 N/A
Recruiting
Piloting an Insomnia Treatment in Patients With Ulcerative Colitis
Condition
Insomnia
Enrollment
20 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT04875429 N/A
Recruiting
Zenith® Fenestrated+ Clinical Study
Condition
Aortic Aneurysm, Abdominal
Enrollment
105 pts
Location
United States, United Kingdom
Sponsor
Cook Research Incorporated
NCT06425029 N/A
Recruiting
Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based...
Condition
Epilepsy
Enrollment
24 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT07384975 Phase 2
Recruiting
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
Condition
Hidradenitis Suppurativa (HS)
Enrollment
150 pts
Location
United States
Sponsor
Navigator Medicines, Inc.
NCT05136196 Phase 2
Recruiting
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Tr...
Condition
Clinical Stage III Cutaneous Melanoma AJCC v8
Enrollment
150 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT05775523 N/A
Recruiting
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatro...
Condition
Growth Hormone Deficiency
Enrollment
500 pts
Location
United States
Sponsor
Ascendis Pharma Endocrinology
NCT05838690 N/A
Recruiting
Optimizing Tracheal Intubation Outcomes and Neonatal Safety
Condition
Infant
Enrollment
3,000 pts
Location
United States, Canada
Sponsor
Children's Hospital of Philade
NCT06172296 Phase 3
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Tre...
Condition
Ganglioneuroblastoma, Nodular
Enrollment
478 pts
Location
United States, Australia, Canada
Sponsor
National Cancer Institute (NCI
NCT06963723 N/A
Recruiting
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients Wi...
Condition
Advanced Cancer
Enrollment
1,000 pts
Location
United States, Puerto Rico
Sponsor
Alliance Foundation Trials, LL
NCT04994756 N/A
Recruiting
Stroke Thrombectomy and Aneurysm Registry
Condition
Stroke
Enrollment
40,000 pts
Location
United States, Canada, Germany
Sponsor
Medical University of South Ca
NCT05147792 N/A
Recruiting
The CONFORM Pivotal Trial
Condition
Atrial Fibrillation
Enrollment
1,600 pts
Location
United States, Czechia, France
Sponsor
Conformal Medical, Inc
NCT06337318 Phase 3
Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor ...
Condition
Classic Follicular Lymphoma
Enrollment
600 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT05564390 Phase 2
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatmen...
Condition
Acute Myeloid Leukemia
Enrollment
2,000 pts
Location
United States, Canada, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT05405413 Phase 2
Recruiting
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
Condition
Cancer
Enrollment
192 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT06752356 Phase 3
Recruiting
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 ...
Condition
Chronic Inflammatory Demyelinating Polyneuropathy
Enrollment
161 pts
Location
United States
Sponsor
Kedrion S.p.A.
NCT05774951 Phase 3
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years ...
Condition
Breast Cancer, Early Breast Cancer
Enrollment
4,300 pts
Location
United States, Argentina, Australia
Sponsor
AstraZeneca
NCT01810913 Phase 2, Phase 3
Recruiting
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizum...
Condition
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
Enrollment
613 pts
Location
United States, Canada, Hong Kong
Sponsor
National Cancer Institute (NCI
NCT03550391 Phase 3
Recruiting
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radioth...
Condition
Brain Metastases
Enrollment
206 pts
Location
United States, Canada
Sponsor
Canadian Cancer Trials Group
NCT07533006 Phase 2
Recruiting
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Los...
Condition
Alopecia Areata
Enrollment
60 pts
Location
United States, Canada, China
Sponsor
Eli Lilly and Company
NCT05820672 N/A
Recruiting
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With...
Condition
Growth Hormone Deficiency
Enrollment
900 pts
Location
United States
Sponsor
Ascendis Pharma Endocrinology
NCT05235165 Phase 3
Recruiting
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients ...
Condition
Metastatic Malignant Neoplasm in the Lung
Enrollment
62 pts
Location
United States, Australia, Canada
Sponsor
Children's Oncology Group
NCT02981628 Phase 2
Recruiting
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma...
Condition
Recurrent B Acute Lymphoblastic Leukemia
Enrollment
80 pts
Location
United States, Puerto Rico
Sponsor
Children's Oncology Group
NCT06898593 N/A
Recruiting
Enhancing Engagement by Integrating Goals and Concerns That Matter to Patients
Condition
Anxiety Disorders
Enrollment
2,448 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
Page 1 of 2 — 48 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology